The effect of leucovorin rescue therapy on methotrexate-induced oral mucositis in the treatment of paediatric ALL: A systematic review

被引:27
作者
Van der Beek, J. N. [1 ]
Oosterom, N. [1 ,2 ]
Pieter, R. [1 ]
de Jonge, R. [3 ,4 ]
van den Heuvel-Eibrink, M. M. [1 ]
Heil, S. G. [2 ]
机构
[1] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands
[2] Erasmus MC Univ, Dept Clin Chem, Med Ctr, Rotterdam, Netherlands
[3] Vrije Univ Amsterdam Med Ctr, Dept Clin Chem, Amsterdam, Netherlands
[4] Amsterdam Med Ctr, Dept Clin Chem, Amsterdam, Netherlands
关键词
Acute lymphoblastic leukemia; Methotrexate; Leucovorin; Oral mucositis; HIGH-DOSE METHOTREXATE; ACUTE LYMPHOBLASTIC-LEUKEMIA; FOLINIC ACID RESCUE; RHEUMATOID-ARTHRITIS; METHYLENETETRAHYDROFOLATE REDUCTASE; CHILDREN; FOLATE; POLYMORPHISMS; EXPOSURE; TOXICITIES;
D O I
10.1016/j.critrevonc.2019.07.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: This study aimed to determine the efficacy of different Leucovorin regimens to reduce oral mucositis in children with acute lymphoblastic leukemia after high-dose Methotrexate (HD-MTX). Methods: Twelve articles were included in a systematic literature review. Articles were categorized into low/medium/high risk of bias. Results: As no randomized controlled trial assessing the effect of Leucovorin has been performed, the efficacy of Leucovorin to reduce oral mucositis remains unknown. Leucovorin was initiated at 24, 36 or 42 h after HD-MTX at a dose of 15 or 30 mg/m(2). No meta-analysis could be performed as treatment regimens differed. When comparing studies with similar HD-MTX doses, we observed lower oral mucositis rates in regimens with higher cumulative doses of Leucovorin and early initiation of Leucovorin after MTX. Conclusion: Even though future studies are necessary, higher cumulative Leucovorin doses and early initiation of Leucovorin after start of MTX seem to reduce oral mucositis.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 41 条
[1]   Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: Relation to oral mucositis [J].
Albertioni, F ;
Rask, C ;
Schroeder, H ;
Peterson, C .
ANTI-CANCER DRUGS, 1997, 8 (02) :119-124
[2]  
[Anonymous], 2015, Common Terminology Criteria for Adverse Events (CTCAE)
[3]   HOW MUCH IS TOO MUCH - FOLINIC ACID RESCUE DOSE IN CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA [J].
BORSI, JD ;
WESENBERG, F ;
STOKLAND, T ;
MOE, PJ .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (08) :1006-1009
[4]   Systemic methotrexate exposure is greater after intrathecal than after oral administration [J].
Bostrom, BC ;
Erdmann, GR ;
Kamen, BA .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (02) :114-117
[5]   How Long Can Folinic Acid Rescue Be Delayed After High-Dose Methotrexate Without Toxicity? [J].
Cohen, Ian Joseph ;
Wolff, Johannes E. .
PEDIATRIC BLOOD & CANCER, 2014, 61 (01) :7-10
[7]   Association of Low Baseline Levels of Erythrocyte Folate With Treatment Nonresponse at Three Months in Rheumatoid Arthritis Patients Receiving Methotrexate [J].
de Rotte, M. C. F. J. ;
de Jong, P. H. P. ;
Pluijm, S. M. F. ;
Calasan, M. Bulatovic ;
Barendregt, P. J. ;
van Zeben, D. ;
van der Lubbe, P. A. ;
de Sonnaville, P. B. ;
Lindemans, J. ;
Hazes, J. M. W. ;
de Jonge, R. .
ARTHRITIS AND RHEUMATISM, 2013, 65 (11) :2803-2813
[8]   Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia [J].
den Hoed, M. A. H. ;
Lopez-Lopez, E. ;
te Winkel, M. L. ;
Tissing, W. ;
de Rooij, J. D. E. ;
Gutierrez-Camino, A. ;
Garcia-Orad, A. ;
den Boer, E. ;
Pieters, R. ;
Pluijm, S. M. F. ;
de Jonge, R. ;
van den Heuvel-Eibrink, M. M. .
PHARMACOGENOMICS JOURNAL, 2015, 15 (03) :248-254
[9]   Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study [J].
Dervieux, T ;
Furst, D ;
Lein, DO ;
Capps, R ;
Smith, K ;
Caldwell, J ;
Kremer, J .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (08) :1180-1185
[10]   HIGH-DOSE METHOTREXATE AS PART OF REMISSION MAINTENANCE THERAPY FOR CHILDHOOD ACUTE LYMPHOCYTIC-LEUKEMIA - A PEDIATRIC ONCOLOGY GROUP PILOT-STUDY [J].
FRANKEL, LS ;
WANG, YM ;
SHUSTER, J ;
NITSCHKE, R ;
DOERING, EJ ;
PULLEN, J .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (12) :804-809